Reasons for Treatment Changes in Patients With Moderate to Severe Psoriasis

被引:5
|
作者
Anderson, Kathryn L. [1 ]
Feldman, Steven R. [1 ,2 ,3 ]
机构
[1] Wake Forest Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27157 USA
[2] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC 27157 USA
[3] Wake Forest Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA
关键词
psoriasis; phototherapy; dermatology; TREATMENT PATTERNS; DRUG SURVIVAL; BIOLOGICS; DISCONTINUATION; POPULATION; ETANERCEPT; ADALIMUMAB; CARE; IMPAIRMENT; THERAPIES;
D O I
10.1177/1203475415572797
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Psoriasis treatment involves multiple treatment arms. Treatment choice depends on many factors and may change, due to the chronicity of psoriasis. Objective: The purpose of our study is to explore reasons for treatment changes in patients with moderate to severe psoriasis. Methods: Ten charts of patients with moderate to severe psoriasis were reviewed. The medication changes and reasons for change were extracted. A treatment change was defined as switching between medication classes, adding or removing a medication class, or switching medications within the oral or biologic medication class. Results: Seventy-seven treatment changes were identified. On average, I treatment change occurred per year of follow-up. The most common reason for treatment change was inadequate disease control. Conclusions: Inadequate disease control with current therapy is the most common reason a physician changes treatment for moderate to severe psoriasis. More efficacious treatments or ways to improve efficacy may help improve the long-term outcomes of psoriasis.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [1] Treatment changes in patients with moderate to severe psoriasis
    Anderson, Kathryn
    Feldman, Steven
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB256 - AB256
  • [2] Treatment Changes in Patients With Moderate to Severe Psoriasis: A Retrospective Chart Review
    Smith, Jaclyn A.
    Wehausen, Brooke
    Richardson, Irma
    Zhao, Yang
    Li, Yunfeng
    Herrera, Vivian
    Feldman, Steven R.
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2018, 22 (01) : 25 - 30
  • [3] Adherence to biologic treatment in patients with moderate to severe psoriasis
    Garcia-Martin, Patricia
    Lamas-Velasco, Mar L.
    Godoy-Trapero, Almudena
    Montes-Torres, Andrea
    Perez-Plaza, Alejandra
    Garcia-Diez, Amaro
    Tello, Esteban Dauden
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB224 - AB224
  • [4] Tailored biological treatment for patients with moderate-to-severe psoriasis
    Maurelli, Martina
    Gisondi, Paolo
    Girolomoni, Giampiero
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (01) : 37 - 43
  • [5] Response to treatment with secukinumab in obese patients with moderate to severe psoriasis
    Krueger, James G.
    Pariser, David
    Muscianisi, Elisa
    Kianifard, Farid
    Steadman, Jennifer
    Sarkar, Rajendra Prasad
    Ehst, Benjamin D.
    Alexis, Andrew F.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB38 - AB38
  • [6] Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis
    Cather, Jennifer Clay
    Young, Chaney T.
    Young, Melody S.
    Cather, J. Christian
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (08) : 983 - 990
  • [7] Pooled efficacy of infliximab for the treatment of patients with moderate to severe psoriasis
    Menter, A
    Papp, K
    Guzzo, C
    Li, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB222 - AB222
  • [8] Treatment Approaches to Moderate to Severe Psoriasis
    Gisondi, Paolo
    Del Giglio, Micol
    Girolomoni, Giampiero
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (11):
  • [9] Ustekinumab for the treatment of moderate to severe psoriasis
    Gospodarevskaya, E.
    Picot, J.
    Cooper, K.
    Loveman, E.
    Takeda, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 61 - 66
  • [10] Risankizumab for the treatment of moderate to severe psoriasis
    Chiricozzi, Andrea
    Antonioli, Luca
    Panduri, Salvatore
    Fornai, Matteo
    Romanelli, Marco
    Blandizzi, Corrado
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (01) : 1 - 8